{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-25-000156","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2025-10-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.877226+00:00","generated_at":"2026-05-17T03:13:48.743331+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Summit plans BLA for ivonescimab in Q4 2025; HARMONi-6 meets endpoint","bullets":["Plans to submit BLA for ivonescimab plus chemotherapy in EGFRm NSCLC in Q4 2025 based on HARMONi study.","HARMONi-6: ivonescimab + chemo reduced risk of progression/death by 40% vs tislelizumab+chemo in 1L squamous NSCLC (HR=0.60, p<0.0001).","HARMONi-3 split into squamous and non-squamous analyses; squamous enrollment completion expected H1 2026, data H2 2026.","New global Phase III HARMONi-GI3 in 1L CRC initiated; targets 600 patients, PFS primary endpoint.","Q3 2025 GAAP net loss $231.8M ($0.31/sh), non-GAAP net loss $101.0M ($0.13/sh); cash $238.6M at Sept 30."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-25-000156","json":"https://secwatch.observer/filing/0001599298-25-000156.json","markdown":"https://secwatch.observer/filing/0001599298-25-000156.md","text":"https://secwatch.observer/filing/0001599298-25-000156.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929825000156/0001599298-25-000156-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929825000156/smmt-20251017.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:13:48.743331+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}